Ash A Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, and leader of the Cancer Genomics Program at Stanford Cancer Institute. His primary research interests are in the development and application of genome technologies and computing (machine learning & data science) to a range of problems in human disease, with special focus on cancer detection, classification, monitoring, and tumor immunology. As a longstanding member of NIH Cancer Genetics (CG) Study Section, he helps the Center for Scientific Review with genome scale studies focused on cancer pathogenesis.
Dr. Alizadeh leads a group interested in techniques and methods for understanding tumor behavior at molecular, cellular, organism and population levels. In this effort, his group studies cancer genomic profiles obtained either from tumor tissues, or from noninvasive “liquid biopsies”. Using machine learning techniques, his lab studies how cellular compositional variation impacts cancer behavior and therapeutic response (e.g., http://cibersortx.stanford.edu, http://precog.stanford.edu, and http://ecotyper.stanford.edu), including anti-tumor immunity (http://maria.stanford.edu).
Dr. Alizadeh's group has helped pioneer a range of noninvasive cancer genomic techniques that enable “liquid biopsies”, including CAPP-Seq (https://cappseq.stanford.edu), PhasED-Seq (https://phasedseq.stanford.edu), and EPIC-Seq (https://epicseq.stanford.edu). Using such techniques work from his group focuses on the analysis of circulating nucleic acids to address problems for early cancer detection (http://clip.stanford.edu) and noninvasive cancer monitoring, including prediction of therapeutic response (http://ciri.stanford.edu & http://direct.stanford.edu).
Dr. Alizadeh holds a BS in Biochemistry from UCLA, an MD from Stanford Medical School, a PhD in Biophysics from Stanford, with additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). He has received a number of key awards for his work, including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, Doris Duke Charitable Research Foundation, among others. He is an elected member of the American Society for Clinical Investigation (ASCI), and an elected member of the Scientific Advisory Board (SAB) of the Lymphoma Research Foundation (LRF).
Dr. Alizadeh is a past-President of the American Society of Hematology (ASH) Meeting on Lymphoma Biology, a founding member of the International Lymphoma ctDNA Consortium & Working Group, and past-Chair of the Scientific Committee on Genetics & Epigenetics for the American Society of Hematology (ASH), and past-Chair the Scientific Committee on Lymphoma & Myeloma for the American Society of Clinical Oncology (ASCO). Dr. Alizadeh is a co-founder of CAPP Medical, CiberMED, and Foresight Diagnostics. Dr. Alizadeh is board certified in Medical Oncology, Hematology, and Internal Medicine, a member of the Stanford Lymphoma Program, and received the Stanford Department of Medicine Research Award in 2005. He is a member of the Scientific Advisory Board for Cell, and Scientific Editor for Blood, Cancer Discovery, Blood Cancer Discovery, and the Journal of Clinical Oncology (JCO) and Precision Oncology (PO).